A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Epratuzumab (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 06 Dec 2016 Pooled retrospective analysis (n=174) of this trial and two other trials (see NCT00117975 and NCT01145495) evaulating effects of early progression of disease was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2015 Pooled exploratory analysis (n=241) of 5 studies including data from this study and 4 other trials (see CTP 700006652, 700009482, 700057042, 70059082) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Aug 2013 Status changed from active, no longer recruiting to completed, according to an Immunomedics media release reporting final results were published online in the journal Cancer on 6 Aug 2013.